×
About 14,889,585 results

American Heart Association Hypertension Guideline Toolkit
http://aha-clinical-review.ascendeventmedia.com/books/aha-high-blood-pressure-toolkit/
American Heart Association

AHA High Blood Pressure Toolkit

Improving Shingles Vaccination Rates in Family Medicine.
https://doi.org/10.12788/jfp.0218
The Journal of Family Practice; Luther JS

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness amo...

Alpha1-antitrypsin deficiency: New therapies on the horizon.
https://doi.org/10.1016/j.coph.2021.06.001
Current Opinion in Pharmacology; Remih K, Amzou S et. al.

Jul 14th, 2021 - Alpha1-antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene, coding for alpha1-antitrypsin (AAT). AAT is synthesised mainly in the liver and is released into bloodstream to protect tissues (particularly lung) with its antiprotease activity. The homozygous Pi∗Z mutation (Pi∗ZZ genotype) is the predominant cause of severe AATD. It interferes with AAT secretion thereby leading...

Central and peripheral arterial diseases in chronic kidney disease: conclusions from a ...
https://doi.org/10.1016/j.kint.2021.04.029
Kidney International; Johansen KL, Garimella PS et. al.

May 8th, 2021 - Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease and events, they are often underrepresented or excluded in clinical trials, leading to important knowledge gaps about how to treat these patients. KDIGO (Kidney Disease: Improving Global Outcomes) conve...

Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 4th, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

ESMO Virtual Congress 2020 Science Weekend Program
https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/session/calendar

Sep 19th, 2020 - ESMO Virtual Congress 2020 Science Weekend Online Program

ESMO Virtual Congress 2020: FAQs
https://www.esmo.org/content/download/313751/6378320/ESMO-Virtual-Congress-2020-FAQs.pdf

Sep 19th, 2020 - ESMO Virtual Congress 2020: Frequently Asked Questions

ESMO
https://www.esmo.org/

Sep 19th, 2020 - EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY The leading professional organisation for medical oncology

ESMO COVID-19 Full Coverage
https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage

Sep 19th, 2020 - The COVID-19 pandemic has brought new challenges to clinical practice and research in oncology. ESMO is reporting on the current situation by news and KOLs experiences, and has gathered useful resources to keep medical oncologists updated.

ESMO Guidelines: COVID-19 Adapted Recommendations Slide Sets
https://www.esmo.org/guidelines/covid-19-adapted-recommendations-slide-sets

Sep 19th, 2020 - The core content of each COVID-19 adapted recommendation is presented in a user-friendly format ready for you to use in your own presentations, both to illustrate your own cases and research, as well as for educational purposes. Please note that while you may use slides individually from the sets for personal use, it is strictly forbidden to alter or hide any of the content, the ESMO logo, the ...

ESMO Virtual Congress 2020: Abstracts
https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

ESMO Virtual Congress 2020: Exhibition
https://www.esmo.org/meetings/esmo-virtual-congress-2020/exhibition

Sep 19th, 2020 - With the new virtual platform, the aim is twofold: on one side to offer an experience which will be able to meet the needs of the many eager to find a fruitful learning opportunity; on the other, we are committed to still offer an engaging networking space, all delivered via state-of-the-art technology. Further information in this regard will be published progressively on this webpage soon.

ESMO: COVID-19 and Cancer
https://www.esmo.org/covid-19-and-cancer?hit=ehp

Sep 19th, 2020 - Updates, guides, webinar series, recommendations, more.

ESMO Webinar Series: Managing Patients in the COVID-19 Era
https://www.esmo.org/meetings/esmo-webinar-series/managing-patients-in-the-covid-19-era

Sep 19th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.

ESMO Virtual Congress 2020: Program
https://www.esmo.org/meetings/esmo-virtual-congress-2020/programme

Sep 19th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.

ESMO Virtual Congress 2020: ESMO Colloquia
https://www.esmo.org/meetings/esmo-virtual-congress-2020/esmo-colloquia

Sep 19th, 2020 - The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

ESMO: COVID-19 and Cancer Care in the ESMO Journals
https://www.esmo.org/covid-19-and-cancer/covid-19-and-cancer-care-in-the-esmo-journals

Sep 18th, 2020 - In this page you can find the articles related to COVID-19 disease in the context of cancer care management as published in the ESMO flagship journal, the Annals of Oncology and the ESMO Open.

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 18th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.

ESMO Virtual Congress 2020: Meeting
https://www.esmo.org/meetings/esmo-virtual-congress-2020

Sep 18th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.

ACR 2020 Permissions and Reprints
https://www.rheumatology.org/Annual-Meeting/Abstracts/Permissions-and-Reprints

Sep 7th, 2020 - ACR Convergence, the ACR's annual meeting, is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, ...

ACR 2020 Frequently Asked Questions
https://www.rheumatology.org/Annual-Meeting/Resources

Sep 7th, 2020 - Please refer to the Frequently Asked Questions (FAQs) below for more information on the all-virtual ACR Convergence 2020. We will share more details as they become available in the coming weeks and months.

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 3rd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768602
JAMA Internal Medicine;

Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 10th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 9th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 8th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Avelumab ‘opens up the door’ for immunotherapy in trophoblastic disease
https://www.healio.com/news/hematology-oncology/20200707/avelumab-opens-up-the-door-for-immunotherapy-in-trophoblastic-disease

Jul 7th, 2020 - A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 7th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 7th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspective on ASCO20 Quality Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200237/full/

Jul 7th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 6th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Expert Perspectives on the ASCO20 Plenary Session
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200236/full/

Jul 6th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 3rd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 3rd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 3rd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 2nd, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 2nd, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

COVID-19 in Immunocompromised Hosts: What We Know So Far
https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa863/5864040
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.

Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200216/full/

Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 25th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Sci...

Breast Cancer Research at ASCO20 Virtual Scientific Program Highlights New Avenues and Better Outcomes
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200222/full/

Jun 25th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 24th, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Clinical Implications of First-Line Pembro for MSI-High mCRC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200220/full/

Jun 24th, 2020 - Long-awaited results from the randomized, phase III KEYNOTE-177 trial provide strong support for using single-agent pembrolizumab instead of a chemotherapy-based regimen in patients newly diagnosed with metastatic colorectal cancer (mCRC) featuring high-level microsatellite instability (MSI-H) or deficient mismatch repair (dMMR; Abstract LBA4).

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 24th, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base that sugg...

Switch Maintenance With Avelumab Changes Treatment Paradigm for Advanced Urothelial Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200217/full/

Jun 24th, 2020 - A switch maintenance therapy approach using the immune checkpoint inhibitor avelumab in patients with advanced urothelial carcinoma (UC) who had not progressed after induction platinum-based chemotherapy offered significantly improved survival outcomes, according to results of the JAVELIN Bladder 100 trial (Abstract LBA1). The study, which was the first UC study ever presented during an ASCO An...

Trastuzumab Achieves Slight Reduction in Recurrence for Women With HER2-Positive DCIS
https://ascopost.com/news/june-2020/trastuzumab-achieves-slight-reduction-in-recurrence-for-women-with-her2-positive-dcis/

Jun 8th, 2020 - The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction in the rate of recurrence among women who received trastuzumab, but this difference was not stati...

RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
https://ascopost.com/news/june-2020/ret-kinase-inhibitor-for-patients-with-solid-tumors-and-ret-genetic-fusions/

Jun 5th, 2020 - The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109).

Results From an Oncology Hospital-at-Home Evaluation
https://ascopost.com/news/june-2020/results-from-an-oncology-hospital-at-home-evaluation/

Jun 5th, 2020 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program. The data demonstrated strong evidence for the benefits of this care model, showing improved patien...

Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk
https://ascopost.com/news/june-2020/remote-pre-and-post-test-genetic-counseling-for-breast-and-ovarian-cancer-risk/

Jun 2nd, 2020 - Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at making genetic testing more accessible. The trial, called MAGENTA (Making GENetic Testing Accessi...

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
https://ascopost.com/news/june-2020/cediranibolaparib-vs-standard-of-care-chemotherapy-for-platinum-sensitive-ovarian-cancer/

Jun 2nd, 2020 - Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients. These results were recently presented by Joyce ...

Durvalumab Added to Standard Chemotherapy Improved Overall Survival in Patients With Malignant Pleural Mesothelioma
https://ascopost.com/news/june-2020/durvalumab-added-to-standard-chemotherapy-improved-os-in-patients-with-malignant-pleural-mesothelioma/

Jun 1st, 2020 - Data from clinical efficacy and biomarker analyses conducted for the single-arm phase II PrE0505 study of the initial treatment of patients with malignant pleural mesothelioma were presented by Patrick Forde, MB, BCh, and colleagues during the Lung Cancer Oral Abstract Session at the ASCO20 Virtual Scientific Program (Abstract 9003). The trial evaluated the addition of durvalumab, an immune che...

Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
https://ascopost.com/news/june-2020/carfilzomib-vs-bortezomib-in-addition-to-lenalidomidedexamethasone-in-newly-diagnosed-multiple-myeloma/

Jun 1st, 2020 - The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim analysis for efficacy and toxicity in the randomized phase III ENDURANCE trial were presented in the P...

Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/alberto-sobrero-on-adjuvant-oxaliplatin-and-fluoropyrimidine-based-therapy-for-stage-iii-colon-cancer/

Jun 1st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-morris-on-the-impact-of-psma-targeted-imaging-on-clinical-management-of-prostate-cancer/

Jun 1st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/neal-shore-on-relugolix-vs-leuprolide-for-advanced-prostate-cancer/

Jun 1st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testosterone recovery after discontinuation, and reduction in cardiovascular side effects (Abstract 5602).

Thierry André, MD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Metastatic Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/thierry-andre-on-pembrolizumab-vs-chemotherapy-for-metastatic-colorectal-cancer/

Jun 1st, 2020 - Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract LBA4).

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy
https://ascopost.com/videos/asco20-virtual-scientific-program/rana-mckay-on-intense-adt-before-radical-prostatectomy/

Jun 1st, 2020 - Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract 5503).

Early local therapy fails to extend survival in metastatic breast cancer subset
https://www.healio.com/hematology-oncology/breast-cancer/news/online/{fce1cd33-c5fd-4bf8-8336-97281967a80c}/early-local-therapy-fails-to-extend-survival-in-metastatic-breast-cancer-subset

Jun 1st, 2020 - Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Adjuvant atezolizumab fails to extend DFS in high-risk urothelial carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{9212b066-b10f-4746-bf88-5ea0cb25b1cf}/adjuvant-atezolizumab-fails-to-extend-dfs-in-high-risk-urothelial-carcinoma

Jun 1st, 2020 - Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

Jun 1st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

Jun 1st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.

VRd Still Reigns in Newly Diagnosed Myeloma
https://www.medpagetoday.com/meetingcoverage/asco/86786

Jun 1st, 2020 - share to facebook share to twitter share to linkedin email article The combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, or VRd, successfully fended off a direct challenge to its position as standard of care in newly diagnosed multiple myeloma.

Add-On Tucatinib Ups Survival in Breast Cancer With Brain Mets
https://www.medpagetoday.com/meetingcoverage/asco/86787

Jun 1st, 2020 - Adding tucatinib (Tukysa) to a trastuzumab-capecitabine (Herceptin-Xeloda) regimen significantly improved central nervous system (CNS) outcomes versus placebo plus trastuzumab-capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases at baseline, researchers reported.

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

Jun 1st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML) in a phase Ib/II trial. The results of the study—presented by Lachowiez et al during the Hematologic Malignancies Oral Abstract Session of the ASCO2...

Early Local Therapy Did Not Extend Survival in Patients With Newly Diagnosed Metastatic Breast Cancer
https://ascopost.com/news/june-2020/early-local-therapy-did-not-extend-survival-in-patients-with-newly-diagnosed-metastatic-breast-cancer/

Jun 1st, 2020 - Women who present at diagnosis with advanced breast cancer have faced an unanswered question: will local therapy, consisting of surgery and radiation to the tumor in the breast, prolong survival compared to the traditional treatment of systemic treatment alone?

Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
https://ascopost.com/videos/asco20-virtual-scientific-program/eric-jonasch-on-a-novel-therapy-for-von-hippel-lindau-disease-associated-rcc/

Jun 1st, 2020 - Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated clear cell renal cell carcinoma as well as responses in other VHL-related lesions (Abstract 5003).

Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program
https://ascopost.com/videos/asco20-virtual-scientific-program/howard-burris-on-highlights-of-the-asco20-virtual-scientific-program/

Jun 1st, 2020 - Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.

Cynthia X. Ma, MD, PhD, on Breast Cancer: Neoadjuvant Endocrine Treatment for ER-Positive, HER2-Negative Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/cynthia-ma-on-neoadjuvant-endocrine-treatment-for-er-positive-her2-negative-breast-cancer/

Jun 1st, 2020 - Cynthia X. Ma, MD, PhD, of Washington University, discusses results from the ALTERNATE trial, which showed neither fulvestrant nor fulvestrant plus anastrozole significantly improved endocrine-sensitive disease rate compared with anastrozole alone in postmenopausal patients with locally advanced estrogen receptor–positive, HER2-negative breast cancer (Abstract 504).

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Selinexor, Bortezomib, and Dexamethasone for Previously Treated Patients
https://ascopost.com/videos/asco20-virtual-scientific-program/meletios-dimopoulos-on-selinexor-bortezomib-and-dexamethasone-for-previously-treated-multiple-myeloma/

Jun 1st, 2020 - Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall response rates compared with twice-weekly bortezomib and dexamethasone in patients previously treated for multiple myeloma (Abstract 8501).

Seema A. Khan, MD, MPH, on Metastatic Breast Cancer: Systemic vs Locoregional Therapies
https://ascopost.com/videos/asco20-virtual-scientific-program/seema-khan-on-systemic-vs-locoregional-therapies-for-metastatic-breast-cancer/

Jun 1st, 2020 - Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, locoregional treatment of the primary tumor did not offer a greater survival benefit than systemic therapy (Abstract LBA2).

Tingyan Shi, MD, PhD, on Ovarian Cancer: Secondary Cytoreductive Surgery for Recurrent Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/tingyan-shi-on-secondary-cytoreductive-surgery-for-recurrent-ovarian-cancer/

Jun 1st, 2020 - Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma
https://www.onclive.com/conference-coverage/asco-2020/imvigor010-misses-primary-endpoint-in-in-miuc

May 31st, 2020 - The phase 3 IMvigor010 trial comparing adjuvant atezolizumab (Tecentriq) with observation in patients with muscle-invasive urothelial carcinoma (MIUC) failed to meet its primary endpoint of disease-free survival (DFS), according to primary analysis data presented at the 2020 ASCO Virtual Scientific Program.

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC
https://www.onclive.com/conference-coverage/asco-2020/longer-followup-for-cemiplimab-confirms-superior-efficacy-over-other-regimens-for-cscc

May 31st, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).

Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
https://www.targetedonc.com/view/final-ananova2-survival-data-support-niraparib-plus-bevacizumab-in-recurrent-ovarian-cancer

May 31st, 2020 - Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology at Rigshopitalet–Copenhagen University Hospital in Denmark and medical director of the Nordic Society of Gynaecological Oncology, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib (Zejula) plus bevacizumab (Avastin) versus niraparib alon...

Avelumab maintenance extends OS in advanced urothelial carcinoma
https://www.healio.com/hematology-oncology/genitourinary-cancer/news/online/{55a121e4-45ae-45ee-a061-27ba8bc78ad8}/avelumab-maintenance-extends-os-in-advanced-urothelial-carcinoma

May 31st, 2020 - Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.

Children with Down syndrome, ALL at higher risk for poor outcomes
https://www.healio.com/hematology-oncology/leukemia/news/online/{4b3c1cc4-4e4a-462e-b738-7ee6b1d20fd3}/children-with-down-syndrome-all-at-higher-risk-for-poor-outcomes

May 31st, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

Axitinib prolongs PFS in metastatic adenoid cystic carcinoma
https://www.healio.com/hematology-oncology/head-neck-cancer/news/online/{40a4c150-78fc-4a61-ae96-5a8b84f9c6ee}/axitinib-prolongs-pfs-in-metastatic-adenoid-cystic-carcinoma

May 31st, 2020 - Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.

BCMA-targeted CAR-T shows ‘outstanding responses’ in advanced multiple myeloma
https://www.healio.com/hematology-oncology/myeloma/news/online/{bc81f18d-afd1-42ae-89ae-185ee74b50be}/bcma-targeted-car-t-shows-outstanding-responses-in-advanced-multiple-myeloma

May 31st, 2020 - Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.

CAR-T continues to show durable responses in indolent non-Hodgkin lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{b5b2d115-7000-4df9-8743-26711c3bbde1}/car-t-continues-to-show-durable-responses-in-indolent-non-hodgkin-lymphoma

May 31st, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.

Progressing malignancy linked to higher mortality among patients with cancer and COVID-19
https://www.healio.com/hematology-oncology/practice-management/news/online/{a24c9adf-558c-4ccb-ba95-8c5a2168dcbe}/progressing-malignancy-linked-to-higher-mortality-among-patients-with-cancer-and-covid-19

May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.

Trastuzumab deruxtecan proves active in HER2-mutated NSCLC
https://www.mdedge.com/hematology-oncology/article/223050/lung-cancer/trastuzumab-deruxtecan-proves-active-her2-mutated

May 31st, 2020 - Among patients with HER2-mutated non–small-cell lung cancer (NSCLC) in an ongoing phase 2 trial, treatment with trastuzumab deruxtecan (T-DXd) has yielded a high response rate, and the median duration of response has not yet been reached, an investigator reported.

ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancer
https://www.mdedge.com/hematology-oncology/article/223052/breast-cancer/alternate-trial-no-fulvestrant-benefit-locally

May 31st, 2020 - Neither fulvestrant alone nor fulvestrant plus anastrozole improved the endocrine-sensitive disease rate (ESDR) versus anastrozole alone as neoadjuvant endocrine therapy in postmenopausal women with locally advanced estrogen receptor-positive HER2-negative (ER+ HER2–) breast cancer in the phase 3 ALTERNATE trial.

Expanding the role of PARP inhibitors in breast cancer
https://www.mdedge.com/hematology-oncology/article/223054/breast-cancer/expanding-role-parp-inhibitors-breast-cancer

May 31st, 2020 - For patients with BRCA-like triple-negative breast cancer (TNBC), adding veliparib to cisplatin chemotherapy may extend survival, based on results from the phase 3 SWOG S1416 trial.

Pyrotinib bests lapatinib in HER2+ metastatic breast cancer
https://www.mdedge.com/hematology-oncology/article/223057/breast-cancer/pyrotinib-bests-lapatinib-her2-metastatic-breast

May 31st, 2020 - The combination of pyrotinib and capecitabine significantly prolonged progression-free survival (PFS), when compared with lapatinib and capecitabine, among patients with previously treated HER2-positive metastatic breast cancer in a phase 3 trial.

First-line doxorubicin plus trabectedin effective, safe for metastatic leiomyosarcoma
https://www.healio.com/hematology-oncology/sarcoma/news/online/{28102d3c-c28b-4f98-950f-daa7db22f27d}/first-line-doxorubicin-plus-trabectedin-effective-safe-for-metastatic-leiomyosarcoma

May 31st, 2020 - Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.

Longer-term imatinib treatment extends OS among patients with GIST
https://www.healio.com/hematology-oncology/sarcoma/news/online/{e2646bcc-d52d-4050-898d-1d3154b179b4}/longer-term-imatinib-treatment-extends-os-among-patients-with-gist

May 31st, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

Add-On Selinexor Boosts PFS in Pretreated Myeloma
https://www.medpagetoday.com/meetingcoverage/asco/86782

May 31st, 2020 - share to facebook share to twitter share to linkedin email article Including the XPO1 inhibitor selinexor (Xpovio) in a weekly bortezomib (Velcade) regimen improved oncologic outcomes and reduced rates of neuropathy in relapsed or refractory multiple myeloma, the phase III BOSTON trial showed.

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 31st, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

Locoregional Treatment of Intact Primary Tumor Does Not Improve Survival, HRQoL in Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200210/full/

May 31st, 2020 - Early initiation of locoregional treatment (LRT) of an intact primary tumor (IPT) in women with de novo stage IV metastatic breast cancer does not appear to prolong survival or improve health-related quality of life (HRQoL) compared with systemic therapy alone, according to a new study (Abstract LBA2). Seema A. Khan, MD, of the Northwestern Memorial Hospital, presented these findings during the...

Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC
https://www.onclive.com/conference-coverage/asco-2020/baseline-and-posttreatment-ctdna-positivity-linked-to-poor-prognosis-rpfs-in-mcrpc

May 31st, 2020 - Baseline and posttreatment circulating tumor DNA (ctDNA) positivity was associated with worse radiologic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to a correlative analysis from the randomized phase 2 A.MARTIN trial presented at the 2020 Virtual Scientific Meeting.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-maintains-efficacy-in-advanced-rcc-irrespective-of-prior-treatment

May 31st, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy regardless of prior therapy, according to data from a pooled analysis of patients treated on the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C20...

Cabozantinib Plus Atezolizumab Shows Promise in mCRPC
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-plus-atezolizumab-shows-promise-in-mcrpc

May 31st, 2020 - The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features, according to findings from the phase 1b COSMIC-021 trial presented during the 2020 ASCO Virtual Scientific Program.

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC
https://www.onclive.com/conference-coverage/asco-2020/darolutamide-improves-os-delays-onset-of-cancer-related-morbidity-and-subsequent-chemo-in-nonmetastatic-crpc

May 31st, 2020 - Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to results of a preplanned final overall survival (OS) analysis of the phase III ARAMIS trial, which were presented during the 2020 ASCO Virtual Scientific Program.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/asco-2020/pyrotinib-combo-improves-pfs-in-her2-mbc

May 31st, 2020 - Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results from the phase 3 PHOEBE trial (NCT03080805) with were presented as part of the 2020 ASCO Virtual Scientific Program.

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC
https://www.onclive.com/conference-coverage/asco-2020/robust-data-and-multivariate-analyses-support-cabazitaxel-as-a-standard-of-care-in-mcrpc

May 31st, 2020 - The use of cabazitaxel (Jevtana) over abiraterone acetate (Zytiga) or enzalutamide (Xtandi) may continue as a standard of care in men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel and either of those 2 androgen receptor (AR)-targeted agents, based on results of a poster presented during the 2020 American Society of Clinical Oncology Virt...

OncLive News Network On Location: ASCO 2020 Day 2
https://www.onclive.com/inside-oncology/asco-2020-news/onclive-news-network-on-location-asco-2020-day-2

May 31st, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Drs Brian Rini and Christopher Sweeney on some significant data being presented in genitourinary cancers, as well as Dr Roy Herbst on some practice-changing lung cancer studies.

Clinically Meaningful Activity Observed With Combination Cabozantinib and Atezolizumab in mCRPC
https://www.targetedonc.com/view/clinically-meaningful-activity-observed-with-combination-cabozantinib-and-atezolizumab-in-mcrpc

May 31st, 2020 - According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features.

ctDNA Positivity Correlates With Poor Survival Outcomes in mCRPC
https://www.targetedonc.com/view/ctdna-positivity-correlates-with-poor-survival-outcomes-in-mcrpc

May 31st, 2020 - Circulating tumor DNA (ctDNA) showing positivity in patients with metastatic castration-resistant prostate cancer (mCRPC) at baseline and posttreatment in the randomized phase 2 A.MARTIN trial was associated with worse radiologic progression-free survival (rPFS), according to a correlative analysis presented at the 2020 Virtual Scientific Meeting.

Darolutamide Demonstrates Improved OS Over Placebo in Phase 3 ARAMIS Trial for Nonmetastatic CRPC
https://www.targetedonc.com/view/darolutamide-demonstrates-improved-os-over-placebo-in-phase-3-aramis-trial-for-nonmetastatic

May 31st, 2020 - Patients with nonmetastatic castration-resistant prostate cancer (CRPC) receiving darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) had a 31% reduction for the risk of death compared with placebo and ADT, according to the results of the phase 3 ARAMIS trial’s preplanned final overall survival (OS) analysis presented during the 2020 ASCO Virtual Scientific Program.